{
  "resourceType" : "MedicationStatement",
  "id" : "PriorSystemicTherapyStatementExample",
  "meta" : {
    "profile" : ["https://nshr-uat.sha.go.ke/fhir/StructureDefinition/nccp-prior-systemic-therapy-statement"]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>5 years of adjuvant tamoxifen for ER+ breast cancer (2018–2023) prior to current recurrence</p></div>"
  },
  "status" : "completed",
  "category" : {
    "coding" : [{
      "system" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs",
      "code" : "HORMONAL-THERAPY",
      "display" : "Hormonal Therapy"
    }]
  },
  "medicationCodeableConcept" : {
    "coding" : [{
      "system" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs",
      "code" : "TAMOXIFEN",
      "display" : "Tamoxifen"
    }]
  },
  "subject" : {
    "reference" : "Patient/example-patient"
  },
  "effectivePeriod" : {
    "start" : "2018-03-01",
    "end" : "2023-02-28"
  },
  "reasonReference" : [{
    "reference" : "Condition/example-condition"
  }],
  "note" : [{
    "text" : "Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021."
  }]
}